专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明公开

EP1238979A4 FUSED HETEROTRICYCLIC COMPOUNDS, PROCESS FOR PREPARING THE COMPOUNDS AND DRUGS CONTAINING THE SAME 有权
标题翻译： ANNE内衬杂环，制法连接和含药
公开(公告)号：EP1238979A4
公开(公告)日：2003-01-15
申请号：EP00983479
申请日：2000-12-13
申请人： EISAI CO LTD
发明人： HIBI SHIGEKI , HOSHINO YORIHISA , YOSHIUCHI TATSUYA , SHIN KOGYOKU , KIKUCHI KOUICHI , SOEJIMA MOTOHIRO , TABATA MUTSUKO , TAKAHASHI YOSHINORI , SHIBATA HISASHI , HIDA TAKAYUKI , HIRAKAWA TETSUYA , INO MITSUHIRO
IPC分类号： A61P1/04 , A61P1/08 , A61P1/10 , A61P1/12 , A61P1/14 , A61P9/04 , A61P9/10 , A61P9/12 , A61P11/00 , C07D471/14 , C07D487/14 , C07D491/14 , A61K31/437 , A61K31/519 , C07D473/02 , C07D495/14
CPC分类号： C07D471/14 , C07D487/14 , C07D491/14
摘要： Compounds represented by general formula (I) are provided, which exhibit antagonism against corticotropin-releasing factor receptor, wherein A, B and C are each independently -(CR1R2)m- (wherein R?1 and R2¿ are each C¿1-6? alkyl or the like, and m is an integer of 1 to 4), -NR?3¿- (wherein R3 is hydrogen or the like), or the like; E and G are each independently a heteroatom such as nitrogen, -(CR6R7)p- (wherein R?6 and R7¿ are each hydrogen or the like, and p is an integer of 0 to 2), or the like; J is a carbon atom substituted with aryl or the like, or a nitrogen atom; K and L are each independently carbon or nitrogen; M is hydrogen, optionally substituted alkyl, or the like; and the partial structures ----- are each a single or double bond.

2. 发明公开

EP1389618A4 PYRAZOLO 1,5-A PYRIDINES AND MEDICINES CONTAINING THE SAME 有权
标题翻译：吡唑并1,5-吡啶和含有药物
公开(公告)号：EP1389618A4
公开(公告)日：2005-07-20
申请号：EP02720608
申请日：2002-04-25
申请人： EISAI CO LTD
发明人： HIBI SHIGEKI , KIKUCHI KOICHI , HOSHINO YORIHISA , SOEJIMA MOTOHIRO , YOSHIUCHI TATSUYA , SHIN KOGYOKU , ONO MUTSUKO , TAKAHASHI YOSHINORI , SHIBATA HISASHI , INO MITSUHIRO , HIRAKAWA TETSUYA
IPC分类号： A61P3/04 , A61P3/10 , A61P9/00 , A61P9/10 , A61P11/00 , A61P15/00 , A61P19/00 , A61P25/08 , A61P25/18 , A61P25/22 , A61P25/24 , A61P25/28 , A61P37/08 , A61P43/00 , C07D471/04 , C07F5/02 , C07F7/22 , A61K31/437 , A61K31/444
CPC分类号： C07D471/04 , A61K31/437 , C07F5/025 , C07F7/2212
摘要： Compounds represented by the general formula (I), salts thereof, and hydrates of both: (I) wherein R1 is methoxy, ethyl, methylthio, or the like; R?2, R3 and R4¿ are each hydrogen, halogeno, or the like; R?5 and R6¿ are each a group represented by the general formula: -X5-X6-X7 (wherein X5 is a single bond or CO-; X6 is a single bond, -NR3a-, or the like; X?7 and R3a¿ are each hydrogen, C¿1-10? alkyl, or the like); and Ar is phenyl, pyridyl, or the like.

3. 发明公开

EP1254904A4 NOVEL PIPERIDINE COMPOUNDS AND DRUGS CONTAINING THE SAME 有权
标题翻译：哌啶和那些含有药物
公开(公告)号：EP1254904A4
公开(公告)日：2003-03-19
申请号：EP01901412
申请日：2001-01-18
申请人： EISAI CO LTD
发明人： OZAKI FUMIHIRO , KANEKO TOSHIHIKO , TABATA MUTSUKO , TAKAHASHI YOSHINORI , MIYAZAKI KAZUKI , KAMATA JUNICHI , YOSHIDA ICHIRO , MATSUKURA MASAYUKI , SUZUKI HIROYUKI , YOSHINAGA TAKASHI , ISHIHARA HIROKI , KATOH HIROSHI , SAWADA KOHEI , ONOGI TATSUHIRO , KOBAYASHI KIYOAKI , OHKUBO MIYUKI
IPC分类号： A61K31/4545 , A61K31/496 , A61K31/5377 , A61P9/04 , A61P9/06 , A61P9/10 , A61P25/02 , A61P25/04 , C07D401/06 , C07D401/14 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14
CPC分类号： C07D401/14 , C07D401/06 , C07D405/14 , C07D409/14 , C07D417/14
摘要： Novel compounds having an excellent Na+ channel inhibiting activity, which are compounds of the general formula (I), salts thereof, or hydrates of both, wherein A is a ring of the general formula (IA), (II) (wherein R1 is hydrogen or the like; and R2 is hydrogen or the like), or the like; W is optionally substituted C¿1-6? alkylene or the like; Z is an optionally substituted C6-14 aromatic carbocyclic group or the like; and l is an integer of 0 to 6.

4. 发明公开

EP1555265A4 7-PHENYL PYRAZOLOPYRIDINE COMPOUNDS 有权转让
标题翻译： 7- PHENYLPYRAZOLOPYRIDINVERBINDUNGEN
公开(公告)号：EP1555265A4
公开(公告)日：2006-08-02
申请号：EP03758781
申请日：2003-10-22
申请人： EISAI CO LTD
发明人： HIBI SHIGEKI , HOSHINO YORIHISA , KIKUCHI KOICHI , SHIN KOGYOKU , TAKAHASHI YOSHINORI , FUJISAWA MASAE , SHIBATA HISASHI , INO MITSUHIRO
IPC分类号： A61K31/437 , A61K31/4545 , A61K31/5377 , A61K31/695 , A61P1/00 , A61P1/04 , A61P1/08 , A61P1/10 , A61P1/12 , A61P5/38 , A61P25/00 , A61P25/18 , A61P25/20 , A61P25/22 , A61P25/24 , C07D471/04 , C07F5/02 , C07F7/18
CPC分类号： C07D471/04 , A61K31/437 , A61K31/4545 , A61K31/5377 , A61K31/695 , C07F5/025 , C07F7/1848
摘要： A compound represented by the following general formula, its salt or hydrates thereof: (I) wherein R1 represents methoxy, methyltio, ethyl, etc.; R5 and R6 independently represent each cyclopropylmethyl, (4-tetrahydropyranyl)methyl, etc.; and two of R40, R41 and R42 are C1-6 alkoxy while the remainder is methoxymethyl, etc. The above compound has an excellent antagonism to a corticotropin-releasing factor receptor.
摘要翻译：由下列通式表示的化合物，其盐或其水合物：（I）其中R1代表甲氧基，甲基，乙基等; R5和R6独立地代表每个环丙基甲基，（4-四氢吡喃基）甲基等; 并且R40，R41和R42中的两个为C1-6烷氧基，而其余为甲氧基甲基等。上述化合物对促肾上腺皮质素释放因子受体具有优异的拮抗作用。

5. 发明公开

EP1364952A4 BICYCLIC NITROGENOUS FUSED-RING COMPOUND 审中-公开
标题翻译：双环含氮化合物稠合环
公开(公告)号：EP1364952A4
公开(公告)日：2005-03-30
申请号：EP02711424
申请日：2002-02-08
申请人： EISAI CO LTD
发明人： HIBI SHIGEKI , TAKAHASHI YOSHINORI , HOSHINO YORIHISA , KIKUCHI KOICHI , SOEJIMA MOTOHIRO , YOSHIUCHI TATSUYA , SHIN KOGYOKU , ONO MUTSUKO , SHIBATA HISASHI , INO MITSUHIRO , HIRAKAWA TETSUYA
IPC分类号： A61P1/14 , A61P3/04 , A61P3/10 , A61P9/00 , A61P9/02 , A61P9/06 , A61P9/10 , A61P9/12 , A61P11/00 , A61P11/06 , A61P13/00 , A61P15/08 , A61P15/10 , A61P15/12 , A61P17/14 , A61P19/10 , A61P21/00 , A61P21/02 , A61P25/00 , A61P25/02 , A61P25/04 , A61P25/06 , A61P25/08 , A61P25/20 , A61P25/28 , A61P25/30 , A61P25/32 , A61P27/00 , A61P27/06 , A61P29/00 , A61P31/18 , A61P35/00 , A61P37/04 , A61P37/08 , A61P43/00 , C07D471/04 , C07D487/04 , A61K31/437 , A61K31/4985 , A61K31/5025 , A61K31/519 , A61K31/5377
CPC分类号： C07D471/04 , C07D487/04
摘要： A novel compound having an excellent antagonistic effect on a corticotropin-releasing-factor receptor. It is a compound represented by the following formula or a salt thereof. (I) In the formula, R1 represents hydrogen, C¿1-6? alkyl, C1-6 alkoxy, etc.; R?2¿ represents halogeno, cyano, nitro, C¿1-10? alkyl, C2-10 alkenyl, C2-10 alkynyl, etc.; R?3¿ represents an optionally substituted C¿6-14? aromatic hydrocarbon group or an optionally substituted, 5- to 14-membered aromatic heterocyclic group; and X, Y, and Z each independently represents nitrogen or CR?4¿ (wherein R4 represents hydrogen, halogeno, cyano, nitro, optionally halogenated C¿1-6? alkyl, etc.), provided that at least two of X, Y, and Z represent CR?4¿.

6. 发明专利

DE60018462T2 未知
公开(公告)号：DE60018462T2
公开(公告)日：2006-02-16
申请号：DE60018462
申请日：2000-12-13
申请人： EISAI CO LTD
发明人： HIBI SHIGEKI , HOSHINO YORIHISA , YOSHIUCHI TATSUYA , SHIN KOGYOKU , KIKUCHI KOUICHI , SOEJIMA MOTOHIRO , TABATA MUTSUKO , TAKAHASHI YOSHINORI , SHIBATA HISASHI , HIDA TAKAYUKI , HIRAKAWA TETSUYA , INO MITSUHIRO
IPC分类号： A61K31/437 , A61K31/519 , A61P1/04 , A61P1/08 , A61P1/10 , A61P1/12 , A61P1/14 , A61P9/04 , A61P9/10 , A61P9/12 , A61P11/00 , C07D471/14 , C07D473/02 , C07D487/14 , C07D491/14 , C07D495/14
摘要： Fused heterocyclic compounds (I) are new. Fused heterocyclic compounds of formula (I) and their salts and hydrates are new. [Image] A, B, D, E, G : N, O, S, (CR 1R 2) m, CO, CS, NR 3, SO or SO 2; R 1, R 2H, Alk, 2-6C alkenyl, 2-6C alkynyl, CycOAlk, AlkOAlk, AlkCyc or 1-6C alkyl-aryl, or CR 1R 23-8 membered ring or is replaced by CR 2=CR 2 or N=CR 2; m : 0-4; Alk : 1-6C alkyl; Cyc : 3-8C cycloalkyl; R 3H, COR 4, S(O) nR 5, Alk 2, optionally substituted aryl or optionally benzene fused Cyc (optionally substituted by 1-4C alkyl); Alk 21-10C alkyl, 2-10C alkenyl or 2-10C alkynyl (all optionally substituted by Q); R 4, R 5Alk or Ar; n : 0-2; J : N, CJ 1, NJ 1 or CJ 1J 1; J 1H, amino, CN, Alk, 1-6C haloalkyl, SO 2NHAlk, aryl or optionally substituted, optionally unsaturated heterocyclyl; K, L : C or N; M : H, halo, CN, Alk 3, NR 11R 12, OR 13, S(O) qR 14, or optionally substituted 2-10C alkenyl, 2-10C alkynyl, aryl or heteroaryl; Alk 3Alk, OAlk or SAlk (all optionally substituted by 1 or more Q); Q : halo, OH, NO 2, CN, COOH, COOAlk, S(O) rR 15, NR 18R 19, Alk, OAlk, Cyc (optionally substituted by 1-4C alkyl), 1-4C alkoxy-1-6C alkyl, 3-8 membered saturated heterocyclyl (optionally substituted by 1-4C alkyl), or optionally substituted aryl or heteroaryl; R 11, R 12H, Alk (optionally substituted by Q), 1-4C alkylacyl or Ar; Ar : optionally substituted aryl-1-4C alkyl, heteroaryl-1-4C alkyl, aryl or heteroaryl; R 13H, Q, 1-4C alkylacyl or Ar; R 14Alk or Ar; q : 0-2; R 15, R 16H Alk (optionally substituted by optionally substituted aryl), 1-4C alkylacyl or Ar; R 18, R 19H, Alk or 1-4C alkylacyl; provided that: (i) KEGJL form a 5 or 6 membered optionally unsaturated ring; and (ii) when K and L = N or K = N, L = C, A, B = CH2 then J is not amino, CN, optionally substituted aminosulfonyl or C(1H-tetrazol-5-yl). ACTIVITY : Antidepressant; tranquilizer; antiinflammatory; hypotensive; gastrointestinal; antiulcer; antiemetic; nootropic; neuroprotective; anabolic; anorectic; antidiabetic; CNS; anticonvulsant; antialcoholic; analgesic; cerebroprotective; auditory; endocrine; vasotropic; cytostatic; anti-HIV; hemostatic; osteopathic; antithyroid; antiasthmatic. MECHANISM OF ACTION : Corticoliberin antagonist. In assays using AtT-20 cells, 8-(1-ethylpropyl)-3-mesityl-2,5-dimethyl-7,8-dihydro-6H-pyrazolo(1,5-a)pyrrolo(3,2-e)pyrimidine (Ia) HCl exhibited an IC 50 value for CRF 1 receptor binding of 100 nM.

7. 发明专利

AT300546T 未知
公开(公告)号：AT300546T
公开(公告)日：2005-08-15
申请号：AT03029058
申请日：2000-12-13
申请人： EISAI CO LTD
发明人： HIBI SHIGEKI , HOSHINO YORIHISA , YOSHIUCHI TATSUYA , SHIN KOBYOKU , KIKUCHI KOICHI , SOEJIMA MOTOHIRO , ONO MUTSUKO , TAKAHASHI YOSHINORI , SHIBATA HISASHI , HIDA TAKAYUKI , HIRAKAWA TETSUYA , INO MITSUHIRO
IPC分类号： A61P1/04 , A61P1/08 , A61P1/10 , A61P1/12 , A61P1/14 , A61P9/04 , A61P9/10 , A61P9/12 , A61P11/00 , C07D471/14 , C07D487/14 , C07D491/14 , C07D473/02 , C07D495/14 , A61K31/437 , A61K31/519
摘要： Fused heterocyclic compounds (I) are new. Fused heterocyclic compounds of formula (I) and their salts and hydrates are new. [Image] A, B, D, E, G : N, O, S, (CR 1R 2) m, CO, CS, NR 3, SO or SO 2; R 1, R 2H, Alk, 2-6C alkenyl, 2-6C alkynyl, CycOAlk, AlkOAlk, AlkCyc or 1-6C alkyl-aryl, or CR 1R 23-8 membered ring or is replaced by CR 2=CR 2 or N=CR 2; m : 0-4; Alk : 1-6C alkyl; Cyc : 3-8C cycloalkyl; R 3H, COR 4, S(O) nR 5, Alk 2, optionally substituted aryl or optionally benzene fused Cyc (optionally substituted by 1-4C alkyl); Alk 21-10C alkyl, 2-10C alkenyl or 2-10C alkynyl (all optionally substituted by Q); R 4, R 5Alk or Ar; n : 0-2; J : N, CJ 1, NJ 1 or CJ 1J 1; J 1H, amino, CN, Alk, 1-6C haloalkyl, SO 2NHAlk, aryl or optionally substituted, optionally unsaturated heterocyclyl; K, L : C or N; M : H, halo, CN, Alk 3, NR 11R 12, OR 13, S(O) qR 14, or optionally substituted 2-10C alkenyl, 2-10C alkynyl, aryl or heteroaryl; Alk 3Alk, OAlk or SAlk (all optionally substituted by 1 or more Q); Q : halo, OH, NO 2, CN, COOH, COOAlk, S(O) rR 15, NR 18R 19, Alk, OAlk, Cyc (optionally substituted by 1-4C alkyl), 1-4C alkoxy-1-6C alkyl, 3-8 membered saturated heterocyclyl (optionally substituted by 1-4C alkyl), or optionally substituted aryl or heteroaryl; R 11, R 12H, Alk (optionally substituted by Q), 1-4C alkylacyl or Ar; Ar : optionally substituted aryl-1-4C alkyl, heteroaryl-1-4C alkyl, aryl or heteroaryl; R 13H, Q, 1-4C alkylacyl or Ar; R 14Alk or Ar; q : 0-2; R 15, R 16H Alk (optionally substituted by optionally substituted aryl), 1-4C alkylacyl or Ar; R 18, R 19H, Alk or 1-4C alkylacyl; provided that: (i) KEGJL form a 5 or 6 membered optionally unsaturated ring; and (ii) when K and L = N or K = N, L = C, A, B = CH2 then J is not amino, CN, optionally substituted aminosulfonyl or C(1H-tetrazol-5-yl). ACTIVITY : Antidepressant; tranquilizer; antiinflammatory; hypotensive; gastrointestinal; antiulcer; antiemetic; nootropic; neuroprotective; anabolic; anorectic; antidiabetic; CNS; anticonvulsant; antialcoholic; analgesic; cerebroprotective; auditory; endocrine; vasotropic; cytostatic; anti-HIV; hemostatic; osteopathic; antithyroid; antiasthmatic. MECHANISM OF ACTION : Corticoliberin antagonist. In assays using AtT-20 cells, 8-(1-ethylpropyl)-3-mesityl-2,5-dimethyl-7,8-dihydro-6H-pyrazolo(1,5-a)pyrrolo(3,2-e)pyrimidine (Ia) HCl exhibited an IC 50 value for CRF 1 receptor binding of 100 nM.

8. 发明专利

NO20052443A 未知
公开(公告)号：NO20052443A
公开(公告)日：2005-07-22
申请号：NO20052443
申请日：2005-05-20
申请人： EISAI CO LTD
发明人： HOSHINO YORIHISA , TAKAHASHI YOSHINORI , HIBI SHIGEKI , KIKUCHI KOICHI , SHIN KOGYOKU , SHIBATA HISASHI , INO MITSUHIRO , FUJISAWA MASAE
IPC分类号： A61K31/437 , A61K31/4545 , A61K31/5377 , A61K31/695 , A61P1/00 , A61P1/04 , A61P1/08 , A61P1/10 , A61P1/12 , A61P5/38 , A61P25/00 , A61P25/18 , A61P25/20 , A61P25/22 , A61P25/24 , C07D471/04 , C07F5/02 , C07F7/18
CPC分类号： C07D471/04 , A61K31/437 , A61K31/4545 , A61K31/5377 , A61K31/695 , C07F5/025 , C07F7/1848

9. 发明专利

BR0313976A 未知
公开(公告)号：BR0313976A
公开(公告)日：2005-07-19
申请号：BR0313976
申请日：2003-10-22
申请人： EISAI CO LTD
发明人： HIBI SHIGEKI , HOSHINO YORIHISA , KIKUCHI KOICHI , SHIN KOGYOKU , TAKAHASHI YOSHINORI , FUJISAWA MASAE , SHIBATA HISASHI , INO MITSUHIRO
IPC分类号： A61K31/437 , A61K31/4545 , A61K31/5377 , A61K31/695 , A61P1/00 , A61P1/04 , A61P1/08 , A61P1/10 , A61P1/12 , A61P5/38 , A61P25/00 , A61P25/18 , A61P25/20 , A61P25/22 , A61P25/24 , C07D471/04 , C07F5/02 , C07F7/18
摘要： A compound represented by the formula: Äwherein R is methoxy, methylthio, ethyl, etc.; R and R are each independently cyclopropylmethyl, (4-tetrahydropyranyl)methyl, etc.; and two of R , R and R are C1-6 alkoxy while the remaining one is methoxymethyl, etc.Ü, a salt thereof, or a hydrate of the foregoing. This compound has excellent antagonism against corticotropin-releasing factor receptor.

10. 发明专利

NZ520041A Novel piperidine compounds and drugs containing the same 未知
公开(公告)号：NZ520041A
公开(公告)日：2004-11-26
申请号：NZ52004101
申请日：2001-01-18
申请人： EISAI CO LTD
发明人： OZAKI FUMIHIRO , KANEKO TOSHIHIKO , TABATA MUTSUKO , TAKAHASHI YOSHINORI , MIYAZAKI KAZUKI , KAMATA JUNICHI , YOSHIDA ICHIRO , MATSUKURA MASAYUKI , SUZUKI HIROYUKI , YOSHINAGA TAKASHI , ISHIHARA HIROKI , KATOH HIROSHI , SAWADA KOHEI , ONOGI TATSUHIRO , KOBAYASHI KIYOAKI , OHKUBO MIYUKI
IPC分类号： A61K31/4545 , A61K31/496 , A61K31/5377 , A61P9/04 , A61P9/06 , A61P9/10 , A61P25/02 , A61P25/04 , C07D401/06 , C07D401/14 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14
摘要： Piperidine compounds of the general formula (I) having an excellent Na+ channel inhibiting activity, salts and hydrates thereof are disclosed, wherein A is a ring of the general formula (IA), (II), wherein R1 and R2 are hydrogen or as defined in the specification),; W is optionally substituted C1-6 alkylene or as defined in the specification; Z is an optionally substituted C6-14 aromatic carbocyclic group or as defined in the specification; and l is an integer of 0 to 6.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式